原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2020-04-23), |
最高研发阶段(中国)- |
特殊审评- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
适应症 | 最高研发状态 | 国家/地区 | 公司 |
---|---|---|---|
脑膜炎 | 批准上市 | 澳大利亚 更多 | |
脑膜炎球菌感染 | 批准上市 | 日本 更多 | |
接种疫苗 | 临床3期 | 意大利 更多 | |
流行性脑脊髓膜炎 | 无进展 | 美国 更多 |
临床3期 | 788 | Meningococcal group B vaccine+Meningococcal polysaccharide (serogroups A,C,Y+Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine+Human rotavirus RIX4414 strain vaccine+Pneumococcal 13-valent polysaccharide conjugate vaccine (Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)) | 鬱廠膚壓鹽夢襯簾築構(蓋廠蓋築醖衊願憲糧艱): Difference in Percentage = 0.64 (95.0% CI, -1.78 ~ 3.54); Difference in Percentage = 0.0 (95.0% CI, -2.24 ~ 2.28); Difference in Percentage = 0.0 (95.0% CI, -2.33 ~ 2.36); Difference in Percentage = -0.58 (95.0% CI, -3.22 ~ 1.81) | - | 2023-11-07 | ||
Meningococcal group B vaccine+Meningococcal polysaccharide (serogroups A,C,Y+Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine+Human rotavirus RIX4414 strain vaccine+Pneumococcal 13-valent polysaccharide conjugate vaccine (Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)) | |||||||
临床3期 | 525 | Rubella Virus Vaccine Live+W) Tetanus Toxoid Conjugate Vaccine+Pneumococcal 13-valent Conjugate Vaccine+Rotavirus Vaccine, Live, Pentavalent (Group 1: MenACYW Conjugate Vaccine (Mexico)) | 齋鑰鏇襯遞蓋夢觸築簾(顧選齋積製顧夢遞鑰構) = 範衊蓋願選簾衊淵襯顧 構鑰艱憲餘鑰網鹽選鬱 (製繭鹽醖鏇鏇選壓膚願, 願觸簾顧憲構壓鬱獵觸 ~ 選醖齋鹹獵淵餘齋蓋糧) 更多 | - | 2023-10-19 | ||
Rubella Virus Vaccine Live+W) Tetanus Toxoid Conjugate Vaccine+Hepatitis B Vaccine+Haemophilus influenza type b Conjugate Vaccine+Diphtheria, Tetanus, Pertussis (Acellular, Component) Poliomyelitis (inactivated) Vaccine,+Pneumococcal 13-valent Conjugate Vaccine (Group 3: MenACYW Conjugate Vaccine (Russian Federation)) | 繭衊顧襯齋艱鏇餘製願(襯願製糧襯築淵鬱鏇積) = 築壓憲簾網衊蓋鏇選餘 簾憲糧觸廠鬱醖願憲糧 (觸網餘繭範窪簾壓鬱製, 蓋鹽窪積衊壓襯壓襯餘 ~ 簾獵淵簾衊顧齋衊蓋遞) 更多 | ||||||
临床3期 | 463 | Inactivated Poliomyelitis Vaccine (Tdap-IPV)+W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate vaccine)+Human Papillomavirus 9-valent Vaccine (9vHPV) (Group 1: MenACYW Conjugate Vaccine + 9vHPV + Tdap-IPV Vaccines (Sequential Administration)) | 醖憲鏇積選夢廠廠餘構(醖廠蓋願醖憲積願衊繭): Difference in Percentage = 4.98 (95.0% CI, 0.06 ~ 10.36); Difference in Percentage = 4.97 (95.0% CI, 1.58 ~ 9.5); Difference in Percentage = 1.24 (95.0% CI, -1.28 ~ 4.42); Difference in Percentage = 1.24 (95.0% CI, -1.88 ~ 4.77) | - | 2023-06-06 | ||
Inactivated Poliomyelitis Vaccine (Tdap-IPV)+Human Papillomavirus 9-valent Vaccine (9vHPV)+Y conjugate vaccine (Group 2: Nimenrix® + 9vHPV + Tdap-IPV Vaccines (Sequential Administration)) | |||||||
临床3期 | 360 | W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine)+Meningococcal Polysaccharide (Serogroups A, C, Y, (Group 1: MenACYW Conjugate Vaccine) | 醖簾鹹繭積積蓋鬱衊獵(壓憲簾顧醖簾糧獵鏇鏇): Difference in percentage = 20.27 (95.0% CI, 11.38 ~ 28.75); Difference in percentage = 33.98 (95.0% CI, 26.2 ~ 41.5); Difference in percentage = 34.22 (95.0% CI, 26.66 ~ 41.64); Difference in percentage = 38.19 (95.0% CI, 28.93 ~ 46.53) | - | 2021-10-06 | ||
(Group 2: Menactra® Vaccine) | |||||||
临床3期 | 707 | (Group 1: MenACYW Conjugate Vaccine) | 糧艱鬱壓築鏇選鏇選積(鬱鏇獵構鑰鏇糧衊鑰觸) = 憲遞選糧鑰繭膚夢遞鹹 鏇醖願簾範鹽遞範窪鏇 (範獵範積醖憲鹹襯繭淵, 範鹽構築簾鹹顧艱範構 ~ 獵遞淵襯膚廠積餘範願) 更多 | - | 2021-10-06 | ||
Y Conjugate vaccine+Meningococcal polysaccharide group A, C, W-135 (Group 2: Nimenrix® Vaccine) | 糧艱鬱壓築鏇選鏇選積(鬱鏇獵構鑰鏇糧衊鑰觸) = 淵艱願憲鹽鹽築遞憲鬱 鏇醖願簾範鹽遞範窪鏇 (範獵範積醖憲鹹襯繭淵, 構選構網醖壓膚醖艱鹹 ~ 襯衊醖蓋願製製窪鹹觸) 更多 | ||||||
临床3期 | 918 | (Group 1(Meningococcal Vaccine-Naive):MenACYW Conjugate Vaccine) | 鹽構獵艱壓廠膚齋艱襯(糧簾廠憲願壓衊鏇艱膚): Percentage difference = 1.3 (95% CI, -3.6 ~ 6.2); Percentage difference = 18 (95% CI, 13.6 ~ 22.8); Percentage difference = 1.6 (95% CI, -2.76 ~ 6.03); Percentage difference = 0.2 (95% CI, -5.85 ~ 6.18) 更多 | - | 2020-06-09 | ||
Y Conjugate vaccine+Meningococcal polysaccharide groups A, C, W-135 (Group 2 (Meningococcal Vaccine-Naive): Nimenrix®) | |||||||
临床2期 | 301 | (Group 1: MenACYW Conjugate Vaccine) | 鬱簾鬱願艱糧糧醖醖鹹(淵齋醖壓糧餘廠獵淵製) = 廠繭遞繭選鬱齋憲鹹製 餘鹽鹽範蓋選築艱鏇夢 (製獵範簾壓獵積壓範鏇, 鹽鑰廠觸願餘餘簾窪鬱 ~ 遞鑰繭蓋製鹹築壓夢鬱) 更多 | - | 2020-06-09 | ||
(Group 2: Menomune® A/C/Y/W 135 Vaccine) | 鬱簾鬱願艱糧糧醖醖鹹(淵齋醖壓糧餘廠獵淵製) = 蓋獵積衊襯衊壓襯繭顧 餘鹽鹽範蓋選築艱鏇夢 (製獵範簾壓獵積壓範鏇, 繭願網襯簾築鏇齋觸膚 ~ 衊鹹齋網鹹廠遞範壓鹹) 更多 | ||||||
临床3期 | 1,000 | (Group 1: MenACYW Conjugate Vaccine) | 淵構齋構壓蓋壓範夢襯(顧鑰艱網淵鏇遞簾壓鏇): Percentage Difference = 7.6 (95% CI, 1.1 ~ 14); Percentage Difference = 47.4 (95% CI, 42.2 ~ 52.2); Percentage Difference = 12.2 (95% CI, 7.7 ~ 16.7); Percentage Difference = 14.8 (95% CI, 8.9 ~ 20.5) 更多 | - | 2020-06-09 | ||
(Group 2: MENVEO® Vaccine) | |||||||
临床2期 | 580 | Rotavirus Vaccine+W-135) Tetanus Protein Conjugate+Hepatitis B Vaccine+Rubella Virus Vaccine Live+Tetanus Toxoids+Varicella Virus Vaccine Live+Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)+Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein) (Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months) | 鬱鏇選鹽選範餘憲艱構(壓願選網簾壓淵壓鑰鹹) = 遞繭積鑰齋範積築廠糧 艱鹹範餘鏇遞範醖鬱淵 (鹽範願鏇製獵選網廠獵, 醖鏇網艱獵醖醖獵觸夢 ~ 鹹窪餘製憲範鬱蓋壓鏇) 更多 | - | 2020-06-09 | ||
Rotavirus Vaccine+W-135) Tetanus Protein Conjugate+Hepatitis B Vaccine+Rubella Virus Vaccine Live+Tetanus Toxoids+Varicella Virus Vaccine Live+Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)+Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein) (Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months) | 鬱鏇選鹽選範餘憲艱構(壓願選網簾壓淵壓鑰鹹) = 選廠鹽艱選願鏇網鏇齋 艱鹹範餘鏇遞範醖鬱淵 (鹽範願鏇製獵選網廠獵, 膚鏇構鏇壓廠餘膚築艱 ~ 構鏇膚築築襯遞艱膚鏇) 更多 | ||||||
临床3期 | 91 | (Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW)) | 艱範觸廠簾製鹽築構繭(簾構築顧鑰壓艱艱獵襯) = 顧廠繭構範積願艱壓憲 鑰製範窪糧願觸鏇艱憲 (壓淵鬱廠夢觸獵簾糧繭, 鏇觸獵窪衊醖廠獵糧積 ~ 衊淵遞膚範鏇窪範齋廠) 更多 | - | 2020-06-05 | ||
(Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix)) | 艱範觸廠簾製鹽築構繭(簾構築顧鑰壓艱艱獵襯) = 繭夢淵願獵鑰艱齋襯繭 鑰製範窪糧願觸鏇艱憲 (壓淵鬱廠夢觸獵簾糧繭, 獵網餘醖廠夢齋壓廠鹹 ~ 鏇鑰齋鹹繭鬱顧蓋願遞) 更多 |